Therapeutic circular dna forms
AssigneeFlagship Pioneering Innovations Vii, LLC
InventorsEdward Matthew Kennedy, Camilo Ayala Breton, Carl Wayne Brown, III, Brian Patrick Mead
Life of this patent
Estimating the term…
Abstract
The disclosure provides, for example, double stranded DNA (dsDNA) molecules comprising one or more chemically modified nucleobases. In some embodiments, the dsDNA molecule is circular and comprises a first strand and a second strand, wherein the first strand comprises one or more chemically modified nucleobases, and the second strand is free of chemically modified nucleobases. In some embodiments, the dsDNA molecule comprises a promoter sequence and an effector sequence that encodes an effector.
Claims30
A pharmaceutical composition comprising a carrier that comprises a double stranded DNA (dsDNA) molecule, wherein:
- (a) the dsDNA molecule is circular;
- (b) the dsDNA molecule comprises a first strand and a second strand, wherein:
- at least 25% of thymine or uracil positions in the first strand of the dsDNA molecule comprise a uracil nucleobase, and
- the second strand is free of chemically modified nucleobases;
- and
- (c) the dsDNA molecule comprises an effector sequence that encodes an effector.
A dsDNA molecule, wherein:
- (a) the dsDNA molecule is circular;
- (b) the dsDNA molecule comprises a first strand and a second strand, wherein:
- at least 25% of thymine or uracil positions in the first strand of the dsDNA molecule comprise a uracil nucleobase, and
- the second strand is free of chemically modified nucleobases;
- and
- (c) the dsDNA molecule comprises an effector sequence that encodes an effector.
A dsDNA molecule, wherein:
- (a) the dsDNA molecule is circular;
- (b) the dsDNA molecule comprises a first strand and a second strand, wherein:
- the first strand comprises one or more chemically modified nucleobases, wherein the chemically modified nucleobase is a chemically modified cytosine nucleobase or a chemically modified guanine nucleobase, and
- the second strand is substantially free of chemically modified nucleobases.
A dsDNA molecule, comprising:
- a promoter region that comprises:
- i) a bidirectional promoter sequence, or ii) a first promoter sequence and a second promoter sequence that are oriented to drive transcription in opposite directions,
- a first effector sequence situated on one side of the promoter region, wherein the first effector sequence has a first strand that comprises one or more chemically modified nucleobases, and a second strand that is substantially free of chemically modified nucleobases, and wherein the first effector sequence encodes a first effector;
- and
- a second effector sequence situated on the other side of the promoter region, wherein the second effector sequence has a first strand that comprises one or more chemically modified nucleobases, and a second strand that is substantially free of chemically modified nucleobases, and wherein the second effector sequence encodes a second effector;
- and
- wherein the bidirectional promoter sequence is operably linked to the first effector sequence and the second effector sequence, or wherein the first promoter sequence is operably linked to the first effector sequence and the second promoter sequence is operably linked to the second effector sequence.
Dependencies are inferred from the claim text.